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Background: Clinical impact of transcranial direct current stimulation (tDCS) alone for
Parkinson’s disease (PD) is still a challenge. Thus, there is a need to synthesize available
results, analyze methodologically and statistically, and provide evidence to guide tDCS
in PD.
Objective: Investigate isolated tDCS effect in different brain areas and number of
stimulated targets on PD motor symptoms.
Methods: A systematic review was carried out up to February 2021, in databases:
Cochrane Library, EMBASE, PubMed/MEDLINE, Scopus, and Web of science. Full text
articles evaluating effect of active tDCS (anodic or cathodic) vs. sham or control on motor
symptoms of PD were included.
Results: Ten studies (n = 236) were included in meta-analysis and 25 studies (n = 405) in
qualitative synthesis. The most frequently stimulated targets were dorsolateral prefrontal
cortex and primary motor cortex. No significant effect was found among single targets on
motor outcomes: Unified Parkinson’s Disease Rating Scale (UPDRS) III – motor aspects
(MD = −0.98%, 95% CI = −10.03 to 8.07, p = 0.83, I² = 0%), UPDRS IV – dyskinesias
(MD = −0.89%, CI 95% = −3.82 to 2.03, p = 0.55, I² = 0%) and motor fluctuations (MD
= −0.67%, CI 95% = −2.45 to 1.11, p = 0.46, I² = 0%), timed up and go – gait (MD =
0.14%, CI 95% = −0.72 to 0.99, p = 0.75, I² = 0%), Berg Balance Scale – balance (MD
= 0.73%, CI 95% = −1.01 to 2.47, p = 0.41, I² = 0%). There was no significant effect of
single vs. multiple targets in: UPDRS III – motor aspects (MD = 2.05%, CI 95% = −1.96
to 6.06, p = 0.32, I² = 0%) and gait (SMD = −0.05%, 95% CI = −0.28 to 0.17, p =
0.64, I² = 0%). Simple univariate meta-regression analysis between treatment dosage
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and effect size revealed that number of sessions (estimate = −1.7, SE = 1.51, z-score
= −1.18, p = 0.2, IC = −4.75 to 1.17) and cumulative time (estimate = −0.07, SE =
0.07, z-score = −0.99, p = 0.31, IC = −0.21 to 0.07) had no significant association.
Conclusion: There was no significant tDCS alone short-term effect on motor function,
balance, gait, dyskinesias or motor fluctuations in Parkinson’s disease, regardless of brain
area or targets stimulated.
Keywords: transcranial direct current stimulation (tDCS), Parkinson’s disease, neuromodulation, motor symptoms,
meta-analysis

INTRODUCTION

elementary reasoning that anodic (a-tDCS) and cathodic
(c-tDCS) stimulation increases or decreases, respectively,
somatic polarity, excitability, and neuronal plasticity (12).
Considering the complex functioning of the brain, the
neurophysiology underlying tDCS is much more heterogeneous.
It can encompass the following: complex forms of plasticity,
involving distinct presynaptic and postsynaptic mechanisms
(long-term potentiation and depression), soma polarization,
dendrites, and synaptic terminals, axonal growth, network effects
(amplifications and oscillations), and functions of interneurons,
endothelial cells, and glia (13). Given the pathophysiological
complexity of PD and the variability of its symptoms, multiple
brain regions can modulate motor recovery, and consequently,
the methods of applying tDCS can be diverging.
Previous reviews investigated tDCS and associated therapies
(14–19), but tDCS alone is still a challenge to determine its
clinical effect on PD (15). Thus, this systematic review and metaanalysis investigated the use of tDCS on PD based on the PICOS
model: population (P): adult patients with PD; intervention (I):
tDCS alone in different brain areas and number of stimulated
nominal targets; comparison (C): control condition, placebo or
sham; outcomes (O): PD motor symptoms; types of studies (S):
clinical trials randomized or not with crossover or parallel design
and open-label studies.

Parkinson’s disease (PD) is a chronic, multisystemic,
neurodegenerative disorder with various mechanisms underlying
its neuropathology (1). PD is standing out as a leading cause of
disability-adjusted life year (DALY) globally (increasing 148%
between 1990 and 2016), the most growing neurological disorder
according to the Global Burden of Disease 2016 (2), and affecting
6.1 million people (3). As an aggravating factor, the forecast
predicts that this number will double in the next generation (3).
Parkinson’s disease is characterized by a triad of cardinal
symptoms (bradykinesia, tremor, and rigidity). Bradykinesia or
slowness of movement is the most characteristic motor symptom
(4), covering many motor manifestations (5). Tremor initially
appears unilateral and progresses to bilateral, worsening in
stressful circumstances or cognitive tasks, and can be attenuated
during sleep or movement (6). Rigidity causes constant or
oscillating resistance to passive joint movement and can be
increased by tasks demanding attention (7).
Among the current treatments available, drug administration
is the most common option. However, a significant
decrease in response to a drug occurs ∼5 years after initial
treatment, worsening motor fluctuations, dyskinesia, dystonia,
incoordination, and arthralgia (9). Neurosurgical procedures
involving deep brain stimulation are another option, but this
method presents high cost (9), surgical risk (8), and possibility
of worsening of verbal fluency and axial motor symptoms
(8, 9). Appropriate interventions present little or no adverse
effects, improve functionality and well-being, and delay the
progression of the disease (9). Thus, new therapeutic approaches
are necessary to provide a better quality of life and to reduce the
financial burden for society and health systems.
Transcranial direct current stimulation (tDCS) has
gained prominence for being a non-invasive, safe, low-cost
neuromodulatory modality, with minimal or no adverse
effect (10, 11). Its mechanisms of action go far beyond the

METHODS
Protocol and Registration
A systematic review with meta-analysis and meta-regression
was performed according to the Cochrane group (20), including
review mechanisms, inclusion or exclusion criteria, search and
selection of articles, analysis of the methodological quality
of included studies, data extraction, and meta-analysis of
results. The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines were adopted (21).
The selection of studies was performed by two independent
reviewers (PCAO and TABA) according to the previously
structured eligibility criteria. Disagreements between reviewers
were resolved by a third reviewer (DGSM). The current review
protocol was registered in the International Prospective Register
of Systematic Reviews – PROSPERO–(https://www.crd.york.
ac.uk/prospero/) under the publicly available registry number
CRD42020188010
(https://www.crd.york.ac.uk/prospero/
display_record.php?ID=CRD42020188010).

Abbreviations: PD, Parkinson’s disease; tDCS, transcranial direct current
stimulation; a-tDCS, anodic transcranial direct current stimulation; c-tDCS,
cathodic transcranial direct current stimulation; DALY, Disability-adjusted life
year; PRISMA, Preferred Reporting Items for Systematic Reviews and MetaAnalyses; PEDro, Physiotherapy Evidence Database; UPDRS, Unified Parkinson’s
Disease Rating Scale; HY, Hoehn and Yahr; FOG, Freezing of gait; MD, Mean
difference; SMD, Standardized mean difference; CI, Confidence interval; DLPFC,
Dorsolateral prefrontal cortex; M1, Primary motor cortex; TUG, Timed up and go;
BBS, Berg Balance Scale.

Frontiers in Neurology | www.frontiersin.org

2

January 2022 | Volume 12 | Article 794784

Oliveira et al.

tDCS Effect on Parkinson’s Disease

Search Strategy

participants and personnel, (d) blinding of outcome assessment,
(e) incomplete outcome data, (f) selective reporting, and (g) other
biases. Each item was classified as “low risk of bias” (“+”), “high
risk of bias” (“–”) or “uncertain risk of bias” (“?”). Disagreements
were resolved by a third reviewer (DGSM).

The following databases were used for this review’s literature
survey: Cochrane Library, EMBASE, PubMed/MEDLINE,
Scopus, and Web of science, and considered the literature
until February 2021. The terms MeSh and operators Booleans
were as follows: “Parkinson’s disease” OR “Parkinson’s disease”
AND “transcranial direct current stimulation” OR “tDCS” OR
“transcranial electrical stimulation” OR “non-invasive brain
stimulation” OR “neuromodulation.” In addition, the reference
lists of selected articles and literature reviews on the subject
were checked to retrieve articles that were not covered by the
database searches.

Data Extraction
Data extraction included sample size (number of individuals
involved), participant characteristics [age, gender, time since PD
diagnosis, Unified Parkinson’s Disease Rating Scale (UPDRS) at
baseline, medication, most affected hemibody, stage Hoehn and
Yahr (HY)], intervention protocol (number of sessions, location
of electrodes, anodic or cathodic, intensity, density, and duration
of stimulation), and outcome measures (gait, motor function,
motor aspects of daily life, dyskinesia, motor fluctuations,
bradykinesia, manual dexterity, upper limb function, balance,
postural stability, and freezing of gait) from all included studies.
Missing article data were requested by email, and those who did
not respond after three attempts or did not provide data for any
reason were excluded from the meta-analysis. Thus, we excluded
15 articles from the quantitative synthesis, 11 for lack of response
(27–37) and 4 for not having or not providing the data (38–41).

Eligibility Criteria
The search was carried out for full text articles, peer-reviewed,
published in scientific journals without language restriction.
However, only studies in English were found. To be included,
studies should (a) include adults (over 18 years of age) with
a clinical diagnosis guided by the Movement Disorder Society
diagnostic criteria for PD (5), all types and levels of severity
or by a clinical definition; (b) apply a-tDCS or c-tDCS; (c)
report motor outcome data only from individuals with PD; (d)
report data on motor outcomes only from the intervention with
tDCS alone (for studies involving multiple interventions); (e)
provide quantitative data for at least one of the outcome measures
(in the manuscript or upon request); (f) have randomized
and non-randomized clinical trials with parallel, crossover, or
open-label design; and (g) have a sham or control condition.
Studies involving research on animals, in vitro or computational
models, were excluded. The agreement between reviewers for the
screening of studies was analyzed using the Kappa (K) statistic,
and the results revealed an “excellent” agreement (K = 0.969; p <
0.0001). The percentage of agreement between the reviewers was
99.9%, and the third reviewer’s tie was 0.1%.

Quantitative Analysis
Quantitative synthesis was performed by combining individual
studies into meta-analyses. We performed analyses comparing
the effect of tDCS alone on motor symptoms according to
the nominal stimulated target and compared the effect on
single or multiple targets. To estimate the effect, we used
continuous post-intervention mean and standard deviation data.
We calculated the mean difference (MD) or the standardized
mean difference (SMD), if the studies assessed the same outcome
using different scales, confidence interval (CI) of 95% for
each comparison, weighted by the inverse variance method
using an effects model random or fixed-effects model, when
applicable. Heterogeneity was assessed using chi-square (p <
0.1 = statistically significant), I² (I² > 75% = significant) and
visual inspection of forest plots. If considerable heterogeneity was
identified (chi-square p < 0.10; I² > 75%), only a qualitative
synthesis would be presented. Review Manager v.5.3 software
(Copenhagen: Nordic Cochrane Center) was used for all data
analysis, except for the meta-regression, performed in Python.
The univariate meta-regression model used a sensitivity analysis
to investigate possible effect moderators related to treatment
characteristics (number of sessions and cumulative time). One
predictor variable was analyzed at a time, and values of p < 0.05
were considered significant.

Study Quality Assessment
The evaluation of the internal validity and presentation of
necessary statistical information of the studies was performed
by two independent reviewers (PCAO and TABA), who used
the classification scale of the Physiotherapy Evidence Database
(PEDro) (22). The PEDro scale consists of 11 items that assess the
followings: (1) eligibility criteria, (2) randomness of groups, (3)
secret allocation, (4) homogeneity between groups, (5) blinding
of participants, (6) blinding of therapists, (7) evaluator blinding,
(8) key outcome in more than 85% of subjects, (9) intention-totreat analysis, (10) statistical comparison between groups, and
(11) precision measure and variability measures. The PEDro scale
is one of the most used instruments in rehabilitation to assess
the methodological quality of clinical trials (23, 24). Thus, it
is a measure with sufficient validity to be used in systematic
reviews of clinical trials and clinical practice guidelines (22). The
classification of the PEDro score was as follows: scores from 0 to
4 = low quality; 4 to 5 = acceptable quality; 6 to 8 = good quality,
and 9 to 10 = excellent quality (25).
The risk of bias was evaluated using the Cochrane risk of
bias assessment (26), which assesses the followings: (a) random
sequence generation, (b) allocation concealment, (c) blinding of
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RESULTS
Overview
This review comprises the range from 1984 to February
2021. The PRISMA flow diagram summarizes steps in the
study identification procedures (Figure 1). The literature search
identified 6,386 studies, and Mendeley software excluded 146
duplicates. No study was included based on verifying the
reference lists of selected articles or literature reviews on the
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FIGURE 1 | PRISMA flowchart of included studies.

(96%) had a sham group (27–38, 40–51) and one (4%) had a
control group, which did not undergo any type of therapy (39).

subject. Forty studies were eligible for full-text reading after
evaluating titles and abstracts. The two most frequent causes
of exclusion were an absence of a comparator and tDCS as
a combined therapy. Another four studies were excluded after
the analysis of abstracts. Studies that investigated non-motor
outcomes after tDCS were also checked for the existence of motor
outcomes for inclusion in the meta-analytic analysis. Finally,
25 studies involving 405 participants met our criteria and were
included in the qualitative synthesis. Of those, 10 were included
in the meta-analysis, covering a total of 236 participants.

Characteristics of Participants
In total, 25 studies included 405 individuals with PD, and the
mean sample size was 17.64 ± 7.40 (ranging from 7 to 26
participants), aged between 58 and 74 years. HY obtained a
minimum score of 1.3 and a maximum of 2.8, indicating early
to almost moderate stages of PD. The UPDRS II achieved a
minimum score of 1.1 and a maximum of 11.6, a UPDRS III
minimum of 13 and a maximum of 39.7, and a minimum of 16
and a maximum of 74.2 on UPDRS’s total score. The duration of
PD had a minimum of 4.3 and a maximum of 12.3 years whereas
the dose of the medication had a minimum of 292.8 mg and a
maximum of 1287.7 mg. Twenty-two (88%) studies performed
the experiment in the ON state of the medication (27–35, 37–
39, 41, 43–51), two (8%) in the OFF state (36, 40) and one (4%)
in both states (42). Details of the participants of each study are
shown in Table 2.

Characteristics of Included Studies
Table 1 summarizes information of included studies, which
investigated the effect of tDCS alone on the motor symptoms of
PD. According to this table, 20 (80%) studies were randomized
(27–29, 32, 34, 36–40, 42–51), four (16%) did not mention
this information (31, 33, 35, 41) and one (4%) used pseudorandomization (30). Twenty studies (80%) had a crossover design
(28–37, 40, 41, 43, 44, 46–51) and five (20%) parallel (27, 38,
39, 42, 45). One (4%) study did not contain information about
blinding (39), three (12%) trials had single-blind experiments
(33, 44, 50), 20 (80%) double-blind experiments (27–32, 34, 36–
38, 40–43, 45–51) and one (4%) double blind in only one of the
experiments (35). Regarding the comparator group, 24 studies

Frontiers in Neurology | www.frontiersin.org

tDCS Protocols
Three (12%) studies stimulated multiple targets, and 22
studies (88%) stimulated single nominal target with dorsolateral
prefrontal cortex (DLPFC) and primary motor cortex (M1)
as the most common montages (Figure 2). In addition, most
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Design

Outcome
measures

Follow-up

N sessions

Nominal target

Target

tDCS Set-up

Results

Albuquerque et al.
(27)

Parallel

PGT, AMT

NO

1

(+): cerebellum &
(–): buccinator
muscle

Single

2 mA, 25 min, ND

Motor
performance (=) in
hand and arm
tasks

Benninger et al.
(42)

Parallel

10MWT, Hand and
arm movements
(bradykinesia),
UPDRS, SRTT

1 and 3 months

8

(+): PMC and MC
& (–): Mastoids
and (+): PFC & (–):
Mastoids Sham:
(+) and (–) 1 cm
apart over the
forehead, two
additional
electrodes
inversely over the
mastoids (not
connected to the
stimulator)

Multi

2 mA, 20 min,
0.021 mA/cm²

↓ in walking time
(ON and OFF) until
1 month later in
the ON group
improvement in
bradykinesia (ON
and OFF) for more
than 3 months (=)
for UPDRS, SRTT

Beretta et al. (28)

Cross

UPDRS, Postural
control
assessment, EMG,
fNIRS, MMSE

NO

5

EMG and CoP
temporal
parameters: (↓)
recovery time x
sham
1

(+): M1
hemisphere
contralateral to the
most affected
body side & (–):
over the
contralateral
supraorbital

Single

1 mA, 20 min, ND

Exp 2

1

(+): M1
hemisphere
contralateral to the
most affected
body side & (–):
over the
contralateral
supraorbital

Single

2 mA, 20 min, ND

EMG and CoP
temporal
parameters: (↓)
onset latency with
2 mA, (↓) recovery
time x sham

1

(+): L-DLPFC &
(–): R-frontal areas

Single

2 mA, 20 min,
0.057 mA/cm²

(=) TUG and video
gait analysis

Cross

TUG, video gait
analysis

NO

(Continued)
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TABLE 1 | Characteristics of the included studies.

Outcome
measures

Follow-up

N sessions

Nominal target

Target

tDCS Set-up

Results

Cosentino et al.
(29)

Cross

FT, upper limb
bradykinesia test,
UPDRS III

NO

2

(+): M1 & (–):
contralateral
orbitofrontal
cortex; (+):
contralateral
orbitofrontal cortex
& (–): M1

Single

2 mA, 20 min, ND

a-tDCS in most
affected
M1:
improvement in FT,
(↓) in Upper Limb
Bradykinesia test
time in both hands,
(↓) in UPDRS III
c-tDCS in less
affected
M1:
improvement in FT,
(↓) in Upper Limb
Bradykinesia test
time in both hands
c-tDCS in most
affected M1: (↑) at
the time of the
upper limb
bradykinesia test

Criminger et al.
(44)

Cross

TUG

NO

1

(+): L-DLPFC &
(–): R-DLPFC

Single

2 mA, 20 min, ND

(=) TUG

da Silva et al. (45)

Parallel

Gait kinematics
analysis, UPDRS III

NO

1

(+): M1 and SMA
& (–): over the
supraorbital area
ipsilateral to the
most affected side

Multi

2 mA, 15 min, ND

(↓) in gait cadence

Dagan et al. (46)

Cross

TUG,
FOG-provoking
test

NO

2

(+): M1 motor
leg-area & (–): ND;
(+): L- DLPFC and
M1 & (–): ND

Single & Multi

2 mA, 20 min, ND

a-tDCS in M1 +
DLPFC: (↓) in
FOG-Provoking
Test and TUG

Doruk et al. (38)

Parallel

UPDRS III, sRT,
4-CRT, PPT, FT,
WT, BU, SP

1 month

10

(+): L-DLPFC &
(–): R-frontal areas;
(+): R-DLPFC &
(–): L-frontal areas

Single

2 mA, 20 min, ND

(=) motor function

Ferrucci et al. (47)

Cross

UPDRS III/IV

1 and 4 weeks

5

(+): M1 bilaterally
& (–): R-deltoid
muscle; (+):
cerebellum & (–):
R-shoulder

Single

2 mA, 20 min, ND

a-tDCS in M1 and
cerebellum
improved
levodopa-induced
dyskinesias
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References

Design

Outcome
measures

Follow-up

N sessions

Nominal target

Target

tDCS Set-up

Results

Fregni et al. (30)

Cross

UPDRS, sRT, PPT

NO

1

(+): M1 dominant
hemisphere & (−):
contralateral
orbitofrontal cortex
(+): contralateral
orbitofrontal cortex
& (–): M1 dominant
hemisphere (+):
DLPFC & (–):
orbitofrontal cortex

Single

1 mA, 20 min, ND

a-tDCS in M1:
improvement
in
UPDRS and sRT,
(=) for PPT
a-tDCS in DLPFC:
significant
main
effect for UPDRS
and sRT, (=) for
PPT
c-tDCS in M1: (=)
for UPDRS, sRT
and PPT

Kaski et al. (48)

Cross

6MWT, gait
velocity, stride
length, TUG, pull
test

NO

1

(+): M1 (leg areas,
10–20% anterior
to Cz) & (–): inion

Single

2 mA, 15 min, ND

(=) gait speed,
stride length, TUG,
6MWT and pull
test

Lattari et al. (49)

Cross

BBS, DGI, TUG

NO

1

(+): L-DLPFC &
(–): R-frontal areas

Single

2 mA, 20 min, ND

a-tDCS improves
balance and
functional mobility
x sham-tDCS

Lawrence et al.
(39)

Parallel

UPDRS II

week 12

4

(+): L-DLPFC &
(–): above the left
eye

Single

1.5 mA, 20 min,
ND

Isolated tDCS did
not generate
significant
improvement in
any motor test

Lu et al. (40)

Cross

UPDRS III, gait
initiation on the
force platform

NO

1

(+): SMA & (–): Fp

Single

1 mA, 10 min,
0.123 mA/cm²

a-tDCS did not
improve self-start
gait in PD and
FOG

Manenti et al. (31)

Cross

TUG

NO

1

(+): L-DLPFC &
(–): R-frontal areas;
(+): R-DLPFC &
(–): L-frontal areas

Single

2 mA, 7 min, 0.057
mA/cm²

(↓) Selective on
TUG reaction
times after a-tDCS
on R-DLPFC and
(=) L-DLPFC

Oliveira et al.
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(Continued)

Design

Outcome
measures

Follow-up

N sessions

Nominal target

Target

tDCS Set-up

Results

Mishra and
Thrasher (32)

Cross

GAITRite (velocity),
phoneme verbal
fluency task

15 and 30 min

1

(+): L-DLPFC &
(–): R-frontal areas

Single

2 mA, 30 min, ND

a-tDCS x sham in
the dual task:
participants
walked
faster
and
generated
a (↑) number of
words/min, at 15
and 30 min after
stimulation
The cost of dual
task
associated
with gait speed
was significantly
(↓) 15 min after
Single task: (=) for
gait and cognitive
performance

Putzolu et al. (33)

Cross

GAITRite

NO

1

(+): L-DLPFC &
(–): R-frontal areas

Single

1.5 mA, 20 min,
ND

Improvement in
gait performance
during cognitive
dual task in the
FOG group

Putzolu et al. (34)

Cross

GAITRite

NO

1

(+): L-DLPFC (–):
orbitofrontal cortex

Single

1.5 mA, 20 min,
ND

Improved stride
length, stride
speed and double
support time

8

References

NO

Salimpour et al.
(35)

Cross

Isometric task,
UPDRS III

NO

1

(+): L-M1 & (–):
R-M1

Single

1 mA, 25 min, 0.04
mA/cm²

-

(Continued)
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(↓)
on
signaldependent noise in
the most affected
arm
(↑) on patients’
willingness to
assign strength to
the most affected
arm and
improvement of
motor symptoms
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TABLE 1 | Continued

Design

Outcome
measures

Follow-up

N sessions

Nominal target

Target

tDCS Set-up

Results

Exp 2

Cross

Isometric task,
UPDRS III

NO

1

(+): R-M1 & (–):
L-M1

Single

2 mA, 25 min, 0.08
mA/cm²

(↓) in the subjective
cost of force
(↑)
in
the
willingness
to
assign force to the
affected side
(↓) in noise
laterality

Exp 3

Cross

Isometric task,
UPDRS III

NO

2

(+): M1
contralateral to the
affected side & (–):
M1 contralateral to
the affected side

Single

2 mA, ND, 0.08
mA/cm²

(↑)
in
the
willingness
to
give strength to
the affected side
(↓) in the laterality
index
(↓) at UPDRS

Exp 4

Cross

Isometric task,
UPDRS III,
PDQ-39

NO

5

(+): M1 ipsilateral
& (–): M1
contralateral to the
affected side

Single

2 mA, ND, 0.08
mA/cm²

c-tDCS
x
sham:
further
improvements in
the laterality index
(↓) higher in the
subjective cost of
strength in the
affected arm
change in
one-hand noise
significant effect
on UPDRS
improvement in
PDQ-39

Schoellmann et al.
(36)

Cross

UPDRS III, EMG,
EEG

30 min

1

(+): M1 & (–):
R-frontal areas

Single

1 mA, 20 min,
<0.1 mA/cm²

Clinical motor
improvement of
the UPDRS III
subtotal (items
22–25) of the MSD
lasting at least 30
min

9

References
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10

References

Design

Outcome
measures

Follow-up

N sessions

Nominal target

Target

tDCS Set-up

Results

Swank et al. (50)

Cross

TUG, PDQ-39,
UPDRS

NO

1

(+): L-DLPFC &
(–): R-DLPFC

Single

2 mA, 20 min, ND

(=) TUG or
PDQ-39

Valentino et al. (37)

Cross

UPDRS III and
total, SWS,
FOG-Q, GFQ

2 days, 2 and 4
weeks

5

(+): M1 (leg area
that starts walking)
& (–): contralateral
orbitofrontal cortex

Single

2 mA, 20 min, ND

Improved gait
(↓) on the number
and duration of
FOG episodes
(↓) in total UPDRS
and III

Verheyden et al.
(41)

Cross

STS, FR, SS180,
TUG, 10MWT

NO

1

(+): M1 of the
dominant
hemisphere & (–):
contralateral
orbitofrontal cortex

Single

1 mA, 15 min, ND

(↓) of speed at
10MWT no
immediate effects
and, in fact, a
possible decline in
motor
performance

Workman et al.
(51)

Cross

25FWT, TUG,
6MWT, BBS,
Posturography

NO

1

Unilateral (+):
Hemisphere
cerebellar more
affected & (–):
Contralateral
upper arm Bilateral
(+): Hemisphere
cerebellar more
affected & (–):
hemisphere
cerebellar
contralateral

Single

2 mA, 20 min, 0.06
mA/cm² 4 mA,
20 min, 0.11
mA/cm²

4 mA bilateral: (↑)
on the BBS
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TABLE 1 | Continued

N, number; PGT, precision grip task; AMT, arm movement task; mA, milliamps; min, minutes; ND, not described; 10MWT, 10 m; UPDRS, Unified Parkinson’s Disease Rating Scale; walk test; SRTT, serial reaction time task; PMC,
premotor cortex; MC, motor cortex; PFC, prefrontal cortex; EMG, electromyography; fNIRS, functional near-infrared spectroscopy; MMSE, mini mental state examination; CoP, center of pressure; Exp, experiment; M1,primary motor
cortex; TUG, timed up and go; L, left; DLPFC, dorsolateral prefrontal cortex; R, right; FT, finger tapping; a-tDCS, anodal transcranial direct current stimulation; c-tDCS, cathodal transcranial direct current stimulation; SMA, supplementary
motor area; FOG, freezing of gait; sRT, simple reaction time; 4-CRT,4-choice reaction time; PPT, Purdue Pegboard test; WT, walking time; BU, buttoning-up; SP, supination–pronation; 6MWT, six-min walk test; BBS, Berg Balance
Scale; DGI, Dynamic Gait Index; Fp, frontal polar; PD, Parkinson’s disease; GAITRite, gait assessment system; PDQ-39, Parkinson’s Disease Questionnaire 39 Items; EEG, electroencephalography; MSD, superior right member; SWS,
stand–walk–sit; FOG-Q, Freezing of Gait Questionnaire; GFQ, Gait and Fall Questionnaire; STS, sit-to-stand; FR, functional reach; SS180, standing-start 180 degrees turning; 25FWT,25-foot walk test; Cross, crossover design; parallel,
parallel design; Single, single target; Multi, multiple targets; (↑), increase; (↓), decrease; (=), equal.
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ON/OFF phase

Active: 584.8 ±
516.2 Sham:
468.5 ± 193.7

20R/2L

ON

Active: 42.5 ±
10.8 Sham: 39.5
± 12.8 (total)
Active: 22.2 ± 8.7
Sham: 17.5 ± 8
(III)

Active: 1024.3 ±
541.5 mg Sham:
1287.7 ±
808.8 mg

ND

ON/OFF

4.84 ± 3.11

36.00 ± 14.32 (III)

545.01 ±
288.59 mg

ND

ON

2.25 ± 0.63

7.80 ± 5.32

11.60 ± 4.00 (II)
22.35 ± 6.77 (III)
33.95 ± 9.44
(total)

ND

ND

ON

58 ± 12.1

ND

ND

ND

386.2 ± 233.5 mg

11R/3L

ON

16 (4 W/12 M)

68.13 ± 9.76

2 ± ND

8.69 ± 9.76

40.31 ± 18.27
(total) 23.44 ±
9.73 (III)

ND

ND

ON

da Silva et al. (45)

17 (7 W/10 M)

Active: 66 ± 5
Sham: 66 ± 10

2.35 ± 0.29

Active: 6 ± 6
Sham: 5 ± 1

ND

ND

ND

ON

Dagan et al. (46)

20 (3 W/17 M)

68.8 ± 6.8

2.5 ± 0.6

9.0 ± 5.7

74.2 ± 23.3 (total)
39.7 ± 14.6 (III)

554.7 ± 401.1 mg

ND

ON

Doruk et al. (38)

18 (6 W/12 M)

61 ± 8

ND

ND

ND

ND

ND

ON

9 (4 W/5 M)

74.33 ± 7.98

2.5 ± 0.35

10.77 ± 2.1

Active Cerebellar:
13 ± 4.9 Active
M1: 13 ± 4.8
Sham: 13.3 ± 4.8
(III)

ND

ND

ON

Fregni et al. (30)

17 (6 W/11 M)

62.3 ± 1.6

2.4 ± 0.2

12.3 ± 1.6

37.4 ± 3.9 (III)

615.0 ± 63.1 mg

9R/8L

ON

Kaski et al. (48)

8 (ND)

ND

ND

ND

25.8 ± 5.74 (total)

ND

ND

ON

Lattari et al. (49)

17 (4 W/13 M)

69.18 ± 9.98

2.35 ± 1.06

7.06 ± 2.70

18.0 ± 8.96 (III)

748.29 ±
343.80 mg

ND

ON

Sample (W/M)

Age (years)

Hoehn and Yahr

Duration of
disease (years)

UPDRS at
baseline

Medication (mg)

Albuquerque et al.
(27)

22 (10 W/12 M)

71.3 ± 8.6

Active: 2.3 ± 0.65
Sham: 2.0 ± 0,63

ND

Active: 24.7 ± 5.7
Sham: 28.4 ±
12.1 (ND)

Benninger et al.
(42)

25 (9 W/16 M)

63.9 ± 8.7

Active: 2.5 ± 0.1
Sham: 2.4 ± 0.2

Active: 10.6 ± 7.1
Sham: 9.1 ± 3.3

Beretta et al. (28)

24 (10 W/14 M)

68.91 ± 8.47

ND

Bueno et al. (43)

20 (8 W/12 M)

64.45 ± 8.98

Cosentino et al.
(29)

14 (6 W/8 M)

Criminger et al.
(44)
11
Ferrucci et al. (47)
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Most affected
hemibody (Right,
Left, Bilateral)

References
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TABLE 2 | Characteristics of participants.

References

Lawrence et al.
(39)

Sample (W/M)

Age (years)

Hoehn and Yahr

Duration of
disease (years)

UPDRS at
baseline

Medication (mg)

Most affected
hemibody (Right,
Left, Bilateral)

ON/OFF phase

tDCS: 7 (5 W/2 M)
control: 7 (4
W/3 M)

tDCS: 72 ± 6.45
control: 72.29 ±
6.21

ND

tDCS: 5.50 ± 5.66
control: 5.36 ±
4.14

tDCS: 1.27 ± 0.56
(II) control: 1.18 ±
0.69 (II)

tDCS: 573.29 ±
586.25 control:
292.88 ± 274.51

ND

ON

OFF

Lu et al. (40)

10 (3 W/7 M)

66.3 ± 9.9

2.7 ± 0.4

7.7 ± 4.0

39.2 ± 17.2 (III)

761.0 ± 362.2 mg

ND

Manenti et al. (31)

10 (4 W/6 M)

67.1 ± 7.2

1.3 ± 1.1

8.1 ± 3.5

13.3 ± 5.7 (III)

749.2 ± 445.5 mg

2R/8L

ON

Mishra and
Thrasher (32)

20 (6 W/14 M)

67.8 ± 8.3

1.9 ± 0.9

4.8 ± 3.8

ND

ND

ND

ON

Putzolu et al. (33)

20: FOG+ (4
W/6 M) FOG- (5
W/5 M)

FOG+: 70.1 ±
3.84 FOG-: 72.8 ±
6.87

ND

FOG+: 9.3 ± 5.5
FOG-: 7.2 ± 5.2

FOG+: 20.1 ± 8.4
(III) FOG-: 22.9 ±
8.1 (III)

ND

ND

ON

Putzolu et al. (34)

21: FOG+ (4
W/6 M) FOG- (4
W/7 M)

FOG+: 69.20 ±
5.20 FOG-: 70.36
± 6.23

FOG+: 2.05 ±
0.44 FOG-: 1.77 ±
0.52

FOG+: 8.00 ±
5.50 FOG-: 5.82 ±
5.29

FOG+: 39.30 ±
11.39 (total) FOG-:
36.27 ± 16.58
(total) FOG+:
18.60 ± 6.38 (III)
FOG-: 20.45 ±
8.15 (III)

ND

ND

ON

ON

Salimpour et al.
(35)
12

Exp 1

10 (4 W/6 M)

59.6 ± 6.68

1.75 ± 0.54

6.9 ± 4.6

15.7 ± 4.8 (III)

515 ± 274.92

Exp 2

10 (2 W/8 M)

61.6 ± 10.76

1.75 ± 0.63

8.5 ± 5.8

18.6 ± 6.09 (III)

655 ± 434.90

10R/0L

Exp 3

10 (4 W/6 M)

60.5 ± 9.16

1.85 ± 0.47

8.3 ± 4.13

24.6 ± 11.21 (III)

740 ± 500.99

8R/1L/1B

Exp 4
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TABLE 2 | Continued

10R/0L

8 (3W/5M)

59.37 ± 9.00

1.5 ± 0.46

6.87 ± 4.96

17.62 ± 4.47 (III)

712.5 ± 470.37

6R/2L

Schoellmann et al.
(36)

10 (4 W/6 M)

64.3 ± 11.4

ND

8.6 ± 4.1

ND

749.15 ±
423.99 mg

7R/3L

OFF

Swank et al. (50)

10 (2W/8M)

68.7 ± 10.2

2 ± ND

7.9 ± 7.1

37.0 ± 12.9 (total)
24.30 ± ND (III)

ND

ND

ON

Valentino et al. (37)

72.3 ± 3.6

2.8 ± 0.5

11 ± 4.9

32 ± 10.3 (III)

ND

4R/6L

ON

20 (ND)

71 ± 7

ND

9±4

16 ± 5 (total)

ND

ND

ON

Workman et al.
(51)

7 (2W/5M)

72.4 ± 6.4

1.9 ± 0.4

4.3 ± 2.5

32.6 ± 14.2 (III)

889.8 ± 497.7 mg

1R/6L

ON

W, women; M, men; UPDRS, Unified Parkinson’s Disease Rating Scale; mg, milligrams; ND, not described; R, right; L, left; FOG, freezing of gait; Exp, experiment.
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10 (5 W/5 M)

Verheyden et al.
(41)
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Meta-Analysis Results
Single Nominal Targets on Motor Symptoms
UPDRS III–Motor Aspects
This analysis included one study (47) and two experiments
divided by nominal target, namely M1 and cerebellum. A total
of nine participants were involved and randomly assigned to one
stimulation protocol at once. There was no significant effect of
tDCS on motor aspects measured by the UPDRS III. Analyzing
the combined effect of these areas (MD = −0.98%, 95% CI
= −10.03 to 8.07, p = 0.83, I² = 0%, without significant
heterogeneity and fixed-effects model), there was no significant
effect about isolated areas (Figure 4A).

UPDRS IV—Dyskinesias
One study (47) enrolled 09 participants and conducted two
experiments in which nominal targets, M1 and cerebellum, were
stimulated. There was no significant effect between tDCS and
dyskinesias assessed by the UPDRS IV. Furthermore, analyzing
the combined effect of these areas (MD = −0.89%, CI 95%
= −3.82 to 2.03, p = 0.55, I² = 0%, without significant
heterogeneity and fixed-effects model), there was also no
significant effect in the analysis of isolated areas (Figure 4B).

FIGURE 2 | Quantity of tDCS studies on PD using single nominal targets, and
example of M1 anodal electrode on C3.

studies performed single tDCS session (66.7%), and others used
2 (11.1%), 4 (3.7%), 5 (11.1%), 8 (3.7%), and 10 sessions (3.7%).
Twenty-two trials (88%) applied anodal tDCS (27, 28, 31–
34, 36–51), whereas three (12%) performed anodal tDCS and
cathodal tDCS (29, 30, 35). The minimum current intensity was
1 mA, the maximum was 4 mA, and the mean duration time of
stimulation per session was 19.28 ± 4.47 min (minimum of 7 min
and maximum of 30 min). Finally, 18 (72%) studies performed
pre- and postintervention assessments (27–31, 33–35, 40, 41,
43–46, 48–51), whereas seven (28%) also performed follow-up
evaluations (range from 15 min to 3 months) (32, 36–39, 42, 47).

UPDRS IV—Motor Fluctuations
Two experiments divided by nominal targets included M1 (47)
and cerebellum (47). A total of 09 participants were involved and
randomly assigned to M1, cerebellum or sham stimulation. There
was no significant effect of tDCS in relation to motor fluctuations,
measured by the UPDRS IV. Analyzing the combined effect of
these areas (MD = −0.67%, CI 95% = −2.45 to 1.11, p = 0.46, I²
= 0%, without significant heterogeneity and fixed-effects model),
there was also no significant effect in the analysis of isolated areas
(Figure 4C).

Motor Outcome Result Measures
Gait was analyzed in 17 (68%) of those studies (31–34, 37, 38, 40–
46, 48–51) and which was evaluated by the timed up and go
(TUG) test, 10-m walk test, video analysis and pressure platform,
six-min walk test, stand–walk–sit test, 25-foot walk test, and
Dynamic Gait Index. Thirteen studies (52%) also investigated the
effect of tDCS alone on UPDRS scores (28–30, 35–40, 42, 45, 47,
50), on bradykinesia, manual dexterity, and upper limb function
(27, 29, 30, 35, 38, 42). Balance or postural stability was analyzed
in five (20%) studies (28, 41, 48, 49, 51) and freezing of gait (FOG)
in other three (12%) studies (37, 40, 47).

TUG—Gait
We analyzed 98 participants distributed in seven studies, grouped
by areas of stimulation, namely DLPFC (43, 44, 49, 50), M1
(46, 48) and cerebellum (51). There was no significant effect
of tDCS in relation to gait, measured by TUG. Analyzing the
combined effect of these areas (MD = 0.14%, CI 95% = −0.72
to 0.99, p = 0.75, I² = 0%, without significant heterogeneity and
random effects model), there was also no significant effect in the
analysis of isolated areas (Figure 4D).

Quality of Included Studies
Internal validity and necessary statistical information were
evaluated using the PEDro scale and obtained a mean score of
8.28 ± 1.24, which reveals a good methodological quality of the
studies (25). Details of the scores for each study are shown in
Table 3.
The results of risk of bias indicate a low or unclear risk
for most studies except for allocation concealment that was
considered high. Details of risk of bias of each study are shown
in Figure 3.
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Berg Balance Scale—Balance
We compared 24 participants and protocol stimulations
distributed in two studies, divided according to the areas of
DLPFC (49) and cerebellum (51). There was no significant effect
of tDCS related to balance, measured by the BBS. Analyzing the
combined effect of these areas (MD = 0.73%, CI 95% = −1.01
to 2.47, p = 0.41, I² = 0%, without significant heterogeneity
and random effects model), there was no significant effect in the
analysis of isolated areas (Figure 4E).

13

January 2022 | Volume 12 | Article 794784

Oliveira et al.

tDCS Effect on Parkinson’s Disease

TABLE 3 | PEDro scale.
Total

Items
1

2

3

4

5

6

7

8

9

10

11
1

Albuquerque et al. (27)

8

1

0

0

1

0

1

1

1

1

1

Benninger et al. (42)

9

1

1

0

1

1

0

1

1

1

1

1

Beretta et al. (28)

9

1

1

0

1

1

0

1

1

1

1

1

Bueno et al. (43)

10

1

1

1

1

1

0

1

1

1

1

1

Cosentino et al. (29)

9

1

1

0

1

1

0

1

1

1

1

1

Criminger et al. (44)

8

1

1

0

1

1

0

0

1

1

1

1

da Silva et al. (45)

10

1

1

1

1

1

0

1

1

1

1

1

Dagan et al. (46)

9

1

1

0

1

1

0

1

1

1

1

1

Doruk et al. (38)

9

1

1

0

1

1

0

1

1

1

1

1

Ferrucci et al. (47)

9

1

1

0

1

1

0

1

1

1

1

1

Fregni et al. (30)

8

1

0

0

1

1

0

1

1

1

1

1

Kaski et al. (48)

8

1

1

0

0

1

0

1

1

1

1

1

Lattari et al. (49)

9

1

1

0

1

1

0

1

1

1

1

1
1

Lawrence et al. (39)

7

1

1

0

1

0

0

0

1

1

1

Lu et al. (40)

9

1

1

0

1

1

0

1

1

1

1

1

Manenti et al. (31)

8

1

0

0

1

1

0

1

1

1

1

1

Mishra and Thrasher (32)

8

0

1

0

1

1

0

1

1

1

1

1

Putzolu et al. (33)

6

0

1

0

1

1

0

0

0

1

1

1

Putzolu et al. (34)

9

1

1

0

1

1

0

1

1

1

1

1

Salimpour et al. (35)

4

0

0

0

0

1

0

0

0

1

1

1

Schoellmann et al. (36)

8

1

1

0

1

1

1

0

0

1

1

1

Swank et al. (50)

8

1

1

0

1

1

0

0

1

1

1

1

Valentino et al. (37)

9

1

1

0

1

1

0

1

1

1

1

1

Verheyden et al. (41)

8

1

0

0

1

1

0

1

1

1

1

1

Workman et al. (51)

8

0

1

0

1

1

0

1

1

1

1

1

Items: (1) eligibility criteria, (2) group randomness, (3) secret allocation, (4) homogeneity between groups, (5) blinding of participants, (6) blinding of therapists, (7) blinding of evaluators,
(8) key result in more than 85% of individuals, (9) analysis of the intention to treat, (10) statistical comparison between groups, and (11) precision measure and variability measures.

Meta-Regression

Single and Multiple Nominal Targets on Motor
Symptoms
UPDRS III—Motor Aspects
We analyzed three studies and four experiments, with 51
participants, grouped according to the number of stimulation
areas: single target (47) and multiple targets (42, 45). There was
no significant effect of tDCS in relation to the motor aspects
assessed by the UPDRS III. Analyzing the combined effect of
these areas (MD = 2.05%, CI 95% = −1.96 to 6.06, p = 0.32, I² =
0%, no heterogeneity and random effects model), there was also
no significant effect in the analysis of isolated areas (Figure 5A).

Simple univariate meta-regression analysis was performed by
a blinded investigator (ACRN) using Python “Pymare” library
to investigate the association between effect size and treatment
dosage considered as the number of sessions and cumulative
time. Analysis revealed that the number of sessions was not
significantly associated with effect size (estimate = −1.7, SE =
1.51, z-score = −1.18, p = 0.2, CI = −4.75 to 1.17). The analysis
also revealed that cumulative time was also not significantly
associated with effect size (estimate = −0.07, SE = 0.07, z-score
= −0.99, p = 0.31, CI = −0.21 to 0.07).

Gait

DISCUSSION

In this analysis, we included 10 studies, with 98 participants,
grouped by the amount of stimulation areas: single target (43, 44,
46, 48–51) and multiple targets (42, 45, 46). The investigation did
not show a significant effect of tDCS, regardless of the number
of nominal targets stimulated, in relation to gait. Analyzing the
combined effect of these areas (SMD = −0.05%, 95% CI = −0.28
to 0.17, p = 0.64, I² = 0%, without significant heterogeneity and
random effects model), there was also no significant effect in the
analysis of isolated areas (Figure 5B).
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This systematic review with meta-analysis and meta-regression
includes 25 studies with 405 participants and investigated the
effect of tDCS on the motor symptoms of PD. Our results
demonstrated that there was no significant effect of tDCS on
short-term motor symptoms of PD, regardless of brain area,
number of stimulated nominal targets, or treatment dosage.
The regions most covered by the included studies were DLPFC
and M1.
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FIGURE 3 | Risk of bias graph (A) and risk of bias summary (B).

The DLPFC is a brain region commonly studied in tDCS
research to observe its effect on non-motor symptoms of PD,
but it has also been widely investigated in motor symptoms.
The justification includes several explanations: (a) the non-motor
symptoms influence the motor symptoms because cognitive
functions are needed to perform motor tasks and are partly
modulated by the DLPFC (31). An example of this relationship
is the execution of the gait, where the individual needs the ability
to perform a dual task (43); (b) DLPFC appears to interfere with
balance, through the attribution of the prefrontal cortex to spatial
orientation (52) in addition to its activation during gait in several
challenging conditions (53, 54). Thus, the hypothesis suggests
that modulating DLPFC can improve visuospatial processing that
improves the balance of individuals with PD (49). However, the
literature shows divergent results related to the stimulation of
this area to improve motor functions. Previous research (30, 38,
39, 43, 44, 50) found no significant effect of tDCS on DLPFC
for motor function, simple reaction time, aspects of isolated and
dual task gait, quality of life, or motor aspects of daily life. In

Frontiers in Neurology | www.frontiersin.org

contrast, other studies (31, 33, 34, 49) found a beneficial effect
for walking alone and with dual task, FOG, functional mobility,
or balance. Finally, responses in DLPFC can activate distinct
networks of motor areas, such as M1, supplementary motor area,
and premotor area, which exert direct control over motor aspects
(55, 56). However, the possibility of cortical functioning through
a matrix cannot be excluded, as in pain processing (12, 57).
In turn, the M1 area is also a widely investigated target for
treatment of motor symptoms of PD, due to its primordial role
in motor control and learning (58). In summary, the disturbance
in the functioning of the basal ganglia causes cortical dysfunction
and promotes the motor symptoms of PD. Thus, the hypothesis
is that the modulation of cortical areas can drive changes in
the cortical–subcortical pathway, positively influencing the basal
ganglia, to correct such dysfunction and reduce symptoms (30).
However, the literature about tDCS in M1 shows divergences.
According to previous studies (29, 30, 35–37, 41, 47), tDCS in
M1 showed a significant effect on hand motor performance,
dyskinesia, gait, FOG, motor function, and simple reaction time,
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FIGURE 4 | Forest plot showing mean difference from the comparison between single targets in motor function—UPDRS III (A) and dyskinesias—UPDRS IV (B) and
motor fluctuations—UPDRS IV (C) and the gait—TUG (D) and balance—BBS (E). Risk of bias was deemed as “low risk of bias” (“+”), “high risk of bias” (“–”), or
“unclear risk of bias” (“?”).
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FIGURE 5 | Forest plot showing mean difference from the comparison between single targets vs. multitarget in motor aspects—UPDRS III (A) and standardized mean
difference in the gait (B). Risk of bias was deemed as “low risk of bias” (“+”), “high risk of bias” (“–”), or “unclear risk of bias” (“?”).

respectively. However, other studies (46, 48) did not obtain a
significant effect on gait and balance.
It is important to note that despite the inaccuracies in the
clinical effect, there is evidence that tDCS stimulates both the
target area and beyond (12). Neurophysiological mechanisms
may include changes in neuronal excitability, plasticity,
neuronal oscillations, and connectivity (12). Numerous
studies using electroencephalography (59–62), functional
magnetic resonance (57, 63–65), combination of transcranial
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magnetic stimulation with electroencephalography (66, 67),
and functional near-infrared spectroscopy (68) have shown
brain changes after tDCS in M1 with modulation of this
neural network.
According to the meta-analysis, it is still not possible to
determine the number of nominal targets to be stimulated in
tDCS protocols to reduce motor symptoms in PD. Considering
pathophysiological mechanisms, chronic evolution, multisystem
repercussions, and varied symptoms, it is necessary to note
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brain regions, shorter interval of hours between sessions, and
evaluation of the long-term effect on simple and complex motor
tasks. Finally, future studies could go beyond the target area and
investigate patterns of cortical activation at baseline and during
treatment to infer possible predictors of response to therapy.
A deeper look at the neurophysiological correlates in patients
with PD is needed, particularly to provide neurophysiological
evidence that cholinergic dysfunction may be an important and
early contributor to motor and cognitive dysfunction in PD.

the importance of functional rehabilitation combined with
additional approaches. The potential of tDCS at disease onset
is also relevant as most motor treatment is provided in the
early phase (during the 1st week and month) (69, 70). Here, we
provide some evidences that tDCS can improve motor function
in early-stage patients to some extent. In previous studies,
early stimulation of tDCS reduced cadence (45), upper limb
bradykinesia (29), FOG (46), and improved levodopa-induced
dyskinesia (47).
There is little evidence regarding the mechanisms of action
of tDCS in the pathophysiology of PD. However, our hypothesis
is that multiple sessions of tDCS associated with rehabilitation
training can activate brain regions by the task-related activity
and, therefore, make them more sensitive to modulation by tDCS
(13). Different hypotheses can explain our results: a) few studies
involving PD, neuromodulation, and motor symptoms aimed
to assess the isolated effect of tDCS. Furthermore, studies that
proposed to investigate such aspects, an even smaller number
presented essential numerical data for a meta-analytic evaluation;
b) our meta-regression showed that the number and cumulative
time of sessions were not associated with tDCS effect size, which
may suggest insufficient corticospinal changes to increase motor
performance and such insufficiency may be associated with other
factors, including long interval of hours between applications
and longer application time, which can inhibit overstimulation
through neuronal counter-regulation, among others (71); (c) the
sample size of the included trials may have been limited to
provide an adequate effect size; and d) there is a lack of evidence
on the non-motor aspects of PD, which may influence the
effectiveness of tDCS on motor outcomes. Thus, it is likely that
cognitive processing is supported by several brain regions and
neural networks, which makes it challenging to identify specific
nominal targets to stimulate. Furthermore, our results cannot
be applicable to individuals in the OFF state of medication,
as most studies (88%) performed their research only in the
ON state.
This systematic review with meta-analysis and metaregression aimed to fill the gaps in the literature related to the
effect of tDCS on the motor symptoms of individuals with PD.
Based on the evidence from previous meta-analyses, our study
(a) provided a direct comparison between the effect sizes of
studies that used motor and non-motor cortical targets, (b)
compared the effects of single montages target vs. multitarget in
motor function, (c) included a larger set of important studies
(27, 28, 32, 34, 36, 40, 51) that bring relevant approaches to the
field under investigation and that were published after previous
reviews were carried out, and (d) analyzed the association of
certain therapeutic variables with tDCS effect size. The recent
evidence-based guidelines for neuromodulation target sites for
the treatment of motor function in PD concludes that anodal
tDCS over motor, premotor, and supplementary motor area is
likely to be effective (level C), whereas on the prefrontal cortex,
there is possibly no efficacy (level B) (15). Thus, considering the
gaps that still exist in the literature and seeking clarification in
future recommendations, further studies should include secret
allocation, adequate blinding, homogeneous comparison group,
sufficient sample size, application of tDCS in single and multiple
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CONCLUSION
In summary, this systematic review with meta-analysis and
meta-regression found no significant short-term effect of tDCS
alone on motor function, balance, gait, dyskinesia, and motor
fluctuations, regardless of brain area or number of stimulated
nominal targets in patients with PD. We also found no
relationship between the effect of tDCS alone and the number
of sessions or cumulative treatment time.
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